Introduction {#Sec1}
============

Mesenchymal stem cells (MSCs) hold great promise in the field of regenerative medicine based on their abilities of self-renewal and multilineage differentiation \[[@CR1]\]. Over the past decade, MSCs which are isolated from the umbilical cord, umbilical cord blood, bone marrow (BM), adipose tissue (AT) and many other adult tissues have been explored as potential therapeutic strategies for a number of diseases \[[@CR2]\], but AT and BM are the most widely used sources of MSC, especially in autologous cell-based therapies due to ease of harvest and potential autologous application \[[@CR3]\]. Moreover, there are a relative abundance of progenitors and a lack of ethical concerns. However, one important question that remains to be answered is which cell is more effective and suitable for cell therapy. Many studies have shown that BMMSCs and ATMSCs share similar features, including the morphologic features and the expression of cell surface antigens, but significant biologic differences have been observed concerning their proliferation rates and differentiation capacities \[[@CR4]-[@CR9]\]. Conflicting results have been reported, with some indicating that the clinical application potential of ATMSCs is more effective or as effective as that of BMMSCs, while others conclude that BMMSCs are superior to ATMSCs \[[@CR7],[@CR10]-[@CR13]\]. Moreover, there are significant differences between ATMSCs and BMMSCs in the cytokine secretome and chemokine receptor expression \[[@CR10],[@CR14],[@CR15]\], which may provide clues to alternative cell sources. One study has demonstrated that ATMSCs are more resistant to *in vitro* apoptosis than BMMSCs \[[@CR11]\].

In these studies, comparative analysis of BMMSCs and ATMSCs is performed in medium supplemented with fetal bovine serum (FBS). FBS is an animal source product, and its use is undesirable due to potential transmission of animal pathogens and the risk that antibodies against FBS are developed, leading to rejection of the transfused cells \[[@CR16]\]. In fact, as much as 20 to 50% of commercial FBS is virus-positive \[[@CR17]\]. It has been shown that a single preparation of 10^8^ MSCs grown in FBS can carry approximately 7 to 30 mg FBS proteins \[[@CR18]\]. At present, the main alternative to FBS-supplemented medium is the use of human reagents enriched with growth factors, namely human platelet lysate (hPL), which increases safety by excluding xenogeneic proteins.

The usage of hPL in MSC culture provides the following advantages: 1) hPL as a human reagent lacks any risk of secondary effects which may be caused by FBS constituents in culture \[[@CR19]\]; and 2) platelet rich plasma (PRP) as a source of hPL can be directly implemented for clinical applications since it is Good Manufacturing Practice-approved without extensive testing \[[@CR20],[@CR21]\].

Several previous studies have been conducted to compare the biological characteristics of BMMSCs and ATMSCs between two different supplemented culture conditions (FBS versus hPL) \[[@CR20],[@CR22]-[@CR26]\]. Based on efficiency and safety, hPL can replace FBS for clinical-scale expansion of functional BMMSCs and ATMSCs for therapeutic applications. Most of the studies report that the growth factor-enriched hPL has considerable growth-promoting properties for MSCs while maintaining their immunophenotype, differentiation potential and immunomodulatory properties \[[@CR20],[@CR23],[@CR26]\]. However, one study reports that MSCs show an increase in osteogenic differentiation and a decrease in adipogenic differentiation when cultured in hPL-supplemented medium \[[@CR26]\]. Moreover, a report illustrates that hPL alters the expression of some relevant MSC surface molecules and leads to a decreased inhibitory capacity on T cell and natural killer cell proliferation and function compared to FBS \[[@CR27]\].

Therefore, the medium used is crucial for the safety and efficacy of MSC culture, and different media used in the culture processes should maintain the different phenotype, differentiation potential, and functions of MSCs during multiple passages \[[@CR28]\]. However, BMMSCs and ATMSCs have not yet been directly compared with each other under hPL conditions for their ability to be used in regenerative medicine applications.

Increasing evidence supports the generalization that stem cell therapy produces generally positive effects largely via secretion of various cytokines, such as growth factors, cytokines and chemokines, involving anti-scarring, anti-apoptotic, angiogenesis, immunomodulatory and chemoattractant functions \[[@CR29]-[@CR31]\].

The aim of this study is to conduct a direct head-to-head comparison of the following biological characteristics of the two types of MSC: morphology, immunophenotype, colony-forming unit-fibroblast (CFU-F) efficiency, proliferation capacity, potential for mesodermal differentiation, and expression of several well-characterized growth factors, cytokines and chemokines *in vitro*. To the best of our knowledge, this is the first study that directly compares human BMMSCs and ATMSCs under hPL conditions. Such information may be crucial for identifying a more suitable cell source for a given clinical application.

Materials and methods {#Sec2}
=====================

Medium preparations {#Sec3}
-------------------

hPL was prepared as previously described \[[@CR32]\]. Briefly, PRP, obtained from one healthy volunteer at the Hospital Transfusion center, was standardized to a concentration of approximately 1 × 10^9^ platelets/mL, and then PRP was frozen down to −80°C and subsequently thawed at 37°C to obtain platelet-released growth factors. Lysed PRP (20 units) was pooled to avoid individual donor variations. hPL was centrifuged at 4,000 g for 15 minutes at 4°C to remove the platelet fragments. The supernatant plasma was filtered further using a 0.22-μm filter (BD Biosciences, San Jose, CA, USA) and added to heparinized Iscove's modified Dulbecco's medium (IMDM; 2 U/mL).

Human bone marrow- and adipose tissue-derived mesenchymal stem cell cultures {#Sec4}
----------------------------------------------------------------------------

All samples were obtained from healthy donors with informed consent, and the study was approved by the Ethics Committee of Military 302 Hospital of China.

BMMSC cultures were established as previously described \[[@CR8]\]. Briefly, BM aspirates (25 mL) were collected from five volunteers aged 18 to 30 years. BM was layered over a lymphoprep gradient and centrifuged at 2,000 rpm for 30 minutes. Mononuclear cells were washed twice with phosphate-buffered saline (PBS) and plated at a concentration of 2 × 10^5^/cm^2^ in 75 cm^2^ flasks for 2 days in 5% hPL-supplemented medium. After removing nonadherent cells, the adherent cells were maintained at 37°C, 5% CO~2~. The medium was subsequently changed twice a week.

ATMSCs were isolated by enzymatic digestion as previously described \[[@CR33]\]. Briefly, lipoaspirate tissues (25 mL) were harvested from five volunteers and washed with PBS in a 50-mL Falcon tube. The tissues were then digested with an equal volume of 0.2% collagenase type IV at 37°C for 30 minutes, and the stromal vascular fraction cells isolated by centrifugation at 300 × g at room temperature. Viable cells (1 × 10^6^) were cultured in 75 cm^2^ flasks in 5% hPL-supplemented medium. After 2 days, the unattached cells were depleted by replacing the medium with fresh medium. The medium was subsequently changed twice a week.

At 80 to 90% confluence, both types of cells were harvested with trypsin-ethylenediaminetetraacetic acid and subsequently replated at 2,000 cells/cm^2^.

Proliferation studies {#Sec5}
---------------------

To compare the proliferative potential of BMMSCs and ATMSCs, both types of cells were serially passaged and counted when a subconfluence of 80 to 90% was reached. The mean population doubling (PD) was determined for each passage using the following formula:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ PD=\frac{\left[ \log 10(Nh)- \log 10(Np)\right]}{ \log 10(2)} $$\end{document}$$where *N*~*h*~ is the collected cell number and *N*~*p*~ is the plated cell number. The PD for each passage was added to the PD of the previous passages to give cumulative population doubling (CPD).

Colony-forming unit-fibroblast assays {#Sec6}
-------------------------------------

To assess the capacity for self-renewal of BMMSCs and ATMSCs, the CFU-F assay was performed as previously described \[[@CR34]\]. Briefly, single-cell suspensions at passage 1 were plated in six-well culture plates in IMDM (5% hPL) at densities of 1 × 10^3^ per well. On day 14, the cell layer was fixed with methanol and stained with crystal violet. Individual colonies composed of at least 50 cells were counted.

Flow cytometry analysis {#Sec7}
-----------------------

For the analysis of surface marker expression of BMMSCs and ATMSCs, both types of cells at passage 5 were washed three times with PBS, and then incubated with a blocking solution of 3% serum in PBS for 30 minutes. After centrifugation, 5 × 10^5^ cells were suspended in blocking solution, then stained with antibodies against human CD14, CD19, CD90, CD105, HLA-DR, CD29, CD13, CD34, CD45 and HLA-ABC (BD Biosciences). After incubation for 30 minutes, the cells were washed with PBS, and then analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, San Jose, CA, USA) following standard procedures.

Multilineage differentiation and staining assay {#Sec8}
-----------------------------------------------

To assess the differentiation potential of BMMSCs and ATMSCs, both types of cells at passage 5 were differentiated into adipocyte, osteoblast, and chondrocyte phenotypes.

For osteogenic differentiation, BMMSCs and ATMSCs were seeded at 5 × 10^3^ cells/cm^2^ for 24 hours, and then cultured in the osteogenic differentiation medium containing 5% hPL, 100 nM dexamethasone, 50 μM ascorbate-2-phosphate, and 10 mM β-glycerophosphate in Dulbecco\'s modified Eagle\'s medium (DMEM). The differentiation medium was subsequently changed twice a week. After 21 days, osteogenic differentiation was assessed by Alizarin Red staining of calcium phosphate deposits.

For adipogenic differentiation, BMMSCs and ATMSCs were seeded at 2 × 10^4^ cells/cm^2^ for 24 hours, and then cultured in the adipogenic differentiation medium containing 5% hPL, 1 μM dexamethasone, 0.2 mM indomethacin, 0.5 mM isobutyl-1-methylxanthine, and 10 mg/L insulin in DMEM. The differentiation medium was subsequently changed twice a week. After 21 days, adipogenic differentiation was assessed by Oil Red O staining of the fatty vacuoles.

For chondrogenic differentiation, 5-μl droplets of cell solution of 2 × 10^7^ cells/mL were seeded in the center of a multi-well plate to form a micromass cultures for 2 hours, and then cultured in the chondrogenic differentiation medium containing 10 mg/L insulin, 10 mg/L transferrin, 5 μg/L sodium selenite, 100 nM dexamethasone, 50 mg/L ascorbate-2-phosphate, 20 ng/mL transforming growth factor (TGF)-β3, 40 mg/L L-proline, 3 mM linoleic acid, 3 mM oleic acid, and 4 g/L human serum albumin in DMEM. The differentiation medium was subsequently changed twice a week. After 21 days, chondrogenic differentiation was assessed by Alcian Blue staining of sulfated proteoglycans.

Real-time polymerase chain reaction analysis {#Sec9}
--------------------------------------------

Real-time PCR was performed to detect the gene expression indicative of cell differentiation. Table [1](#Tab1){ref-type="table"} lists the primers that were used. Power SYBR Green PCR Master mix (Applied Biosystems, Fostrt City, CA, USA) was used under the following conditions: 50°C for 2 minutes, 95°C for 2 minutes, and then 95°C for 3 seconds and 60°C for 30 seconds for a total of 40 cycles. Results were analyzed using the 2^-∆Ct^ method relating gene expression to β-actin.Table 1**Primer sequences for real-time PCR analysis and their respective product sizesGenePrimer sequence (5′ to 3′)Product size (bp)**RUNX-2GGAGTGGACGAGGCAAGAGTTT133AGCTTCTGTCTGTGCCTTCTGGAlkaline phosphataseGGGAACGAGGTCACCTCCAT67TGGTCACAATGCCCACAGATSOX-9GTACCCGCACTTGCACAAC139GTAATCCGGGTGGTCCTTCTCollagen IIGGCAATAGCAGGTTCACGTACA79CGATAACAGTCTTGCCCCACTTPPARγGGCTTCATGACAAGGGAGTTTC74AACTCAAACTTGGGCTCCATAAAGLPLGAGGTACTTTTCAGCCAGGATGTAAC82AGCTGGTCCACATCTCCAAGTCβ-actinTGACGTGGACATCCGCAAAG205CTGGAAGGTGGACAGCGAGG

Enzyme-linked immunosorbent assay {#Sec10}
---------------------------------

To compare protein secretion between BMMSCs and ATMSCs, the production of inflammatory cytokines (such as tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-6), chemokines (such as stem cell-derived factor-1 (SDF-1) and IL-8), and growth factors (such as basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-1, and vascular endothelial growth factor (VEGF)) were measured. Both types of cells (1 × 10^5^ cells/well) at passage 5 were seeded on 24-well culture plates in hPL-free IMDM medium for 48 hours. The supernatants were collected, and the concentrations were measured with human enzyme-linked immunosorbent assay (ELISA) kits (R&D, Minneapolis, MN, USA), according to the manufacturer's instructions.

Mixed lymphocyte culture assays {#Sec11}
-------------------------------

To quantify and compare the immunomodulatory effects of BMMSCs and ATMSCs, both types of cells were first treated with mitomycin C (50 μg/ml for 50 minutes) to inactivate the proliferation. Next, human peripheral blood mononuclear cells were prepared by centrifugation on a Ficoll-Hypaque density gradient, and 2 × 10^5^ cells of mononuclear cells were co-cultured with 2 × 10^3^, 5 × 10^3^, and 1 × 10^4^ BMMSCs and ATMSCs per well in 96-well culture plate with 1 μg/ml anti-CD3 and anti-CD28 T-cell activating mAbs (Life Technologies, Carlsbad, CA, USA) for 72 hours at 37°C and 5% CO~2~. Conditioned medium was collected for the evaluation of indoleamine 2,3-dioxygenase (IDO) activity and prostaglandin E~2~ (PGE~2~) and TGF-β quantification. PGE~2~ and TGF-β concentrations were quantified using ELISA (R&D), according to the manufacturer's instructions. IDO activity was evaluated by Kynurenine levels as previously described \[[@CR35]\]. Kynurenine levels are directly proportional to IDO activity.

Statistical analysis {#Sec12}
--------------------

The data are presented as the means ± standard deviations of at least three experiments. Statistical analyses between groups were carried out using a Student's *t*-test. *P* \< 0.05 was considered to indicate a statistically significant difference.

Results {#Sec13}
=======

Morphology of bone marrow- and adipose tissue-derived mesenchymal stem cells {#Sec14}
----------------------------------------------------------------------------

The adherent cells from BM and AT formed several colonies and exhibited a heterogeneous morphology with various shapes, including discoidal flat, triangular, and elongated. After passage 3, both types of cells became relatively homogeneous and showed a similar fibroblast-like (elongated spindle) morphology with abundant cytoplasm and large nuclei. BMMSCs and ATMSCs grew in parallel or vortex-like patterns, and no morphologic differences were observed in the final cell morphology (Figure [1](#Fig1){ref-type="fig"}).Figure 1Morphology of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells cultivated in human platelet lysate-supplemented medium. BMMSCs and ATMSCs were tiny, slender, and bright. Scale bar = 100 μm.

Proliferation capacity of bone marrow- and adipose tissue-derived mesenchymal stem cells {#Sec15}
----------------------------------------------------------------------------------------

CPD analysis showed that ATMSCs possessed higher CPD numbers for each passage, compared with BMMSCs (all *P* \< 0.05), indicating that ATMSCs had greater proliferative potential than BMMSCs (Figure [2](#Fig2){ref-type="fig"}A). At passage 5, CPD of ATMSCs and BMMSCs reached 13.7 ± 0.5 and 17.2 ± 0.3, respectively (*P* \< 0.01).Figure 2Proliferation capacity of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human platelet lysate-supplemented medium. **(A)** Cumulative population doublings of BMMSCs and ATMSCs. **(B)** Colony-forming unit-fibroblast (CFU-F) number of BMMSCs and ATMSCs cultivated in human platelet lysate-supplemented medium at densities of 1,000 per well. All values are shown as means ± standard deviation; n = 5. \**P* \< 0.05, \*\**P* \< 0.01. n.s., not significant.

CFU-F analyses showed no significant difference in colony counts between BMMSCs and ATMSCs (*P* \> 0.05; Figure [2](#Fig2){ref-type="fig"}B), although ATMSCs proliferated more rapidly than BMMSCs. Moreover, there were no significant differences in the cell number of each colony between BMMSCs and ATMSCs (data not shown).

Immunophenotypic analysis of bone marrow- and adipose tissue-derived mesenchymal stem cells {#Sec16}
-------------------------------------------------------------------------------------------

Flow cytometry analysis showed that BMMSCs and ATMSCs expanded in hPL-supplemented medium exhibited specific MSC markers (CD13, CD105) and cell adhesion molecules (CD29, CD90) at high levels (\>85%), and hematopoietic cell markers (CD14, CD19, CD34, CD45) molecules at very low levels (\<0.5%). Moreover, both types of cells expressed HLA-ABC (\>85%) but not HLA-DR (\<0.5%) (Table [2](#Tab2){ref-type="table"}). A representative phenotypic analysis of BMMSCs and ATMSCs is shown in Figure [3](#Fig3){ref-type="fig"}, demonstrating the homogeneity of the phenotype. In summary, BMMSCs and ATMSCs in hPL-supplemented medium reveal very similar expression patterns of surface markers.Table 2**Comparison of the expression of surface markers of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells as analyzed by flow cytometrySurface markersExpression (%)BMMSCs (n = 5)ATMSCs (n = 5)**CD1399.78 ± 0.6199.17 ± 0.57CD2998.36 ± 0.5098.28 ± 1.04CD9099.48 ± 0.4399.03 ± 0.47CD10587.38 ± 0.6290.31 ± 0.82HLA-ABC94.34 ± 1.5195.94 ± 3.51CD140.23 ± 0.170.18 ± 0.20CD190.16 ± 0.080.10 ± 0.48CD340.07 ± 0.020.05 ± 0.04CD450.08 ± 0.030.20 ± 0.15HLA-DR0.15 ± 0.110.26 ± 0.17Figure 3Immunophenotype of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human platelet lysate-supplemented medium. Flow cytometry analysis showed that BMMSCs and ATMSCs consistently stained positive for CD13, CD29, CD90, CD105, and HLA-ABC and did not react with CD14, CD19, CD34, CD45, and HLA-DR (n = 5; one representative example shown).

Differentiation of bone marrow- and adipose tissue-derived mesenchymal stem cells into osteocytes, chondrocytes and adipocytes {#Sec17}
------------------------------------------------------------------------------------------------------------------------------

To explore the differentiation potential towards osteoblasts, adipocytes, and chondrocytes of BMMSCs and ATMSCs expanded in hPL-supplemented medium, cytochemical staining and real-time PCR were performed to detect the cell differentiation capacity.

Calcium deposits of BMMSCs and ATMSCs after 21 days of differentiation were visualized by Alizarin Red staining, but the amount of staining was higher in BMMSCs than that in ATMSCs (Figure [4](#Fig4){ref-type="fig"}A). Furthermore, BMMSCs differentiated toward osteoblasts showed a statistically significant higher expression of RUNX-2 and alkaline phosphatase than ATMSCs (both *P* \< 0.05; Figure [4](#Fig4){ref-type="fig"}B). This indicates that BMMSCs have a higher osteogenic capability compared with ATMSCs.Figure 4Osteogenic differentiation potential of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human platelet lysate-supplemented medium. **(A)** Alizarin Red staining of BMMSCs and ATMSCs. Magnification × 100. **(B)** Quantitative assessment of mRNA expression. Values are shown as mean ± standard deviation; n = 5. *\*P* \< 0.05.

Sulfated proteoglycans of BMMSCs and ATMSCs after 21 days of differentiation were visualized by Alcian Blue staining, but the amount of staining was higher in BMMSCs than that in ATMSCs (Figure [5](#Fig5){ref-type="fig"}A). Furthermore, BMMSCs differentiated toward chondrocytes showed a statistically significant higher expression of SOX-9 and collagen II than ATMSCs (both *P* \< 0.01; Figure [5](#Fig5){ref-type="fig"}B). This indicates that BMMSCs have a higher chondrogenic capability compared with ATMSCs.Figure 5Chondrogenic differentiation potential of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human platelet lysate-supplemented medium. **(A)** Alcian Blue staining of BMMSCs and ATMSCs. Magnification × 100. **(B)** Quantitative assessment of mRNA expression. Values are shown as mean ± standard deviation; n = 5. *\*\*P* \< 0.01.

Fatty vacuole deposits of BMMSCs and ATMSCs after 21 days of differentiation were visualized by Oil Red O staining; no significant differences in the amount of staining were observed between two types of cells (Figure [6](#Fig6){ref-type="fig"}A). Furthermore, the BMMSCs differentiated toward adipocytes showed statistically similar mRNA expression of PPARγ and LPL as ATMSCs (both *P* \> 0.05; Figure [6](#Fig6){ref-type="fig"}B). This indicates that BMMSCs and ATMSCs have similar adipogenic capability.Figure 6Adipogenic differentiation potential of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human platelet lysate-supplemented medium. **(A)** Oil Red O staining of BMMSCs and ATMSCs. Magnification × 200. **(B)** Quantitative assessment of mRNA expression. Values are shown as mean ± standard deviation; n = 5. n.s., not significant.

Expression analysis of cytokines, growth factors, and chemokines of bone marrow- and adipose tissue-derived mesenchymal stem cells {#Sec18}
----------------------------------------------------------------------------------------------------------------------------------

To compare the protein secretion between BMMSCs and ATMSCs, ELISA was used to investigate the secretion of several cytokines, growth factors, and chemokines from ATMSC and BMMSC cultures. Compared with BMMSCs, ATMSCs secreted significantly greater amounts of IGF-1 (*P* \< 0.01), bFGF (*P* \< 0.05), and IFN-γ (*P* \< 0.05). On the other hand, BMMSCs secreted significantly greater amounts of SDF-1 (*P* \< 0.01) and HGF (*P* \< 0.01). However, there were no significant differences between ATMSCs and BMMSCs for several secreted factors, including inflammatory cytokines such as IL-6 and TNF-α \[[@CR31]\], chemokines such as IL-8 \[[@CR36]\], and growth and angiogenic factors such as VEGF \[[@CR37]\] (*P* \> 0.05; Figure [7](#Fig7){ref-type="fig"}).Figure 7Quantification of cytokines, growth factors, and chemokines (pg/10^5^ cells) of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells. Values are shown as mean ± standard deviation; n = 5. \**P* \< 0.05, \*\**P* \< 0.01. bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; n.s., not significant; SDF-1, stem cell-derived factor-1; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

Immunomodulatory factor expression of bone marrow- and adipose tissue-derived mesenchymal stem cells {#Sec19}
----------------------------------------------------------------------------------------------------

When cultured in three different MSC numbers, ATMSCs in hPL medium exhibited greater IDO activity (all *P* \< 0.01) compared with BMMSCs. However, no significantly difference in TGF-β (all *P* \> 0.05) and PGE~2~ (all *P* \> 0.05) secretion was observed between the two types of cell (Figure [8](#Fig8){ref-type="fig"}).Figure 8Quantification of immunomodulatory factor (pg/mL) of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells. Values are shown as mean ± standard deviation; n = 5. \**P* \< 0.01. MSC, mesenchymal stem cell; n.s., not significant; PGE~2~, prostaglandin E~2~; TGF, transforming growth factor.

Discussion {#Sec20}
==========

Our findings demonstrate a number of findings. (1) BMMSCs and ATMSCs expanded in hPL-supplemented medium exhibit a homogeneous population with similar fibroblast-like (elongated spindle) morphology. (2) ATMSCs expanded in hPL-supplemented medium have greater proliferative potential than BMMSCs, while there are no significant differences in colony efficiency between the two types of cells. (3) BMMSCs and ATMSCs in hPL-supplemented medium reveal very similar expression patterns of surface markers. (4) BMMSCs expanded in hPL-supplemented medium possess higher capacity toward osteogenic and chondrogenic differentiation compared with ATMSCs, while they both have similar adipogenic differentiation potential. (5) There are some differences between BMMSCs and ATMSCs for several secreted proteins, such as cytokines, growth factors, and chemokines. (6) ATMSCs have more potent immunomodulatory effects than BMMSCs.

The plastic adherence capacity, surface marker expression, and multilineage differentiation potential towards osteoblasts, adipocytes, and chondrocytes have been proposed as minimal criteria to characterize human MSCs by the International Society for Cellular Therapy \[[@CR38]\]. In the present study, we use hPL for production of MSCs and analyze all these parameters, and the results favor the "true MSC nature" of BMMSCs and ATMSCs. Moreover, the two types of cells exhibit homogeneous cell populations with a similar morphology and the expression of surface markers. Many investigators have demonstrated that MSCs isolated by adherence and cultured in FBS exhibit different cell morphology, representing heterogeneous populations \[[@CR39]\]. In this study, both BMMSCs and ATMSCs exhibit heterogeneous morphology with various shapes at the first hPL-supplemented culture phase, with the morphology becoming gradually homogeneous with successive passages. Both types of cells show a similar fibroblast-like (elongated spindle) morphology in parallel or vortex-like patterns. The possibility of some resting mature cell types within the MSC layer after the first step and the high proliferative rate leads to the culture of successive passages to obtain a large amount of pure MSCs. In addition, a possibility is that MSCs in hPL-supplemented medium are thinner and smaller in morphology and size compared with those in FBS \[[@CR23]\]. In the present study, BMMSCs and ATMSCs in hPL-supplemented medium are positive for specific MSC markers (CD13, CD105) and cell adhesion molecules (CD29, CD90) in agreement with earlier reports. Furthermore, MSCs are very low (\<0.5%) in all hematopoietic cell markers such as CD14, CD19, CD34, and CD45, showing that BMMSCs and ATMSCs in hPL-supplemented medium have little or no hematopoietic cell contamination. This result is lower than the minimal criteria proposed by the International Society for Cellular Therapy (\<2%) and that reported in FBS-supplemented medium, further suggesting BMMSCs and ATMSCs in hPL-supplemented medium are nearly homogeneous populations compared with those in FBS-supplemented cultures. Interestingly, both types of cells express HLA-ABC (\>90%) but not HLA-DR (\<0.5%), consistent with the result under FBS-supplemented culture in previous reports. Both BMMSCs and ATMSCs reveal very similar expression patterns of surface markers in agreement with the FBS-based comparative phenotypic analysis described earlier \[[@CR40],[@CR41]\].

Multilineage differentiation potential is the most well-established characteristic of MSCs and thus is considered the hallmark of these cells. In the present study, BMMSCs in hPL-supplemented culture exhibit superior capacity for osteogenic and chondrogenic differentiation but a similar capacity for adipogenic differentiation when compared with ATMSCs. According to comparative analysis of multilineage differentiation of BMMSCs and ATMSCs in FBS-supplemented medium as described earlier, similar patterns of osteogenic and chondrogenic differentiation are demonstrated between the two types of cells in FBS-supplemented medium \[[@CR42]\]. On the contrary, ATMSCs have higher adipogenic differentiation potential than BMMSCs \[[@CR42]\], but similar adipogenic differentiation capacity between the two types of cells in FBS-supplemented medium is also reported \[[@CR43]\]. This may be related to the different differentiation medium and cell passage.

Cell-based therapies need viable and ample numbers of cells for regenerative medicine. In this study, we aim to optimize MSC culture under xeno-free conditions and scale up MSCs in preparation for potential clinical use. Sufficient quantities of MSCs can be scaled up in hPL-supplemented cultures in 5 passages at a seeding density of 2,000 cells/cm^2^, considering that a 75-kg patient needs approximately 1 to 5 × 10^6^ MSCs per kilogram body weight for transplantation. Based on a clinical point of view, we therefore suggest that MSCs at passage 5 be used for evaluation of their characteristics. For autologous therapies, the cells should be available soon after injury. In hPL-supplemented cultures, ATMSCs exhibit a significantly greater number of PD than BMMSCs, showing the higher proliferative potential of ATMSCs. Similar patterns were seen in FBS as described previously \[[@CR43]\], but a previous study has reported that BMMSCs in FBS show more PD than ATMSCs in passages 2 to 5 \[[@CR41]\]. In addition, BMMSCs in the hPL yield similar CFU numbers as ATMSCs. A previous study has reported that the abundance of CFU-F of ATMSCs in FBS is significantly greater than that of BMMSCs \[[@CR39]\], but another study shows that BMMSCs form more colonies than ATMSCs in passage 3 \[[@CR41]\]. A possible explanation might be that several rich growth factors in hPL can stimulate colonies \[[@CR24]\].

It has been suggested that the administration of MSC-derived conditioned medium in experimental models of acute organ injury is as effective as the administration of MSCs in some cases \[[@CR44],[@CR45]\], indicating essential participation of paracrine mechanisms in diminishing pathology. These paracrine factors include different types of cytokines, such as growth factors, inflammatory cytokines and chemoattractants \[[@CR46]\]. Increasing evidence supports the notion that the mechanism of functional benefit after MSC implantation is predominantly dependent on paracrine effects \[[@CR29]-[@CR31]\]. We thus compare the expression of growth factors, cytokines and chemokines in BMMSCs and ATMSCs expanded in hPL-supplemented conditions, and find a suitable cell source for cell therapy. bFGF, HGF, IGF-1, and VEGF, several well-demonstrated growth factors in cell-based tissue repair, are recently shown to be effective in different models of acute renal, lung, hepatic, myocardial and neural injury \[[@CR29]\]. However, their in-depth paracrine mechanisms require further elucidation. Further studies comparing the importance of these four growth factors for the repair of different types of tissues are necessary to determine which growth factor is more effective for specific applications. BMMSCs secrete higher levels of HGF, but lower levels of bFGF and IGF-1, and similar levels of VEGF compared with ATMSCs. The potential for minimally invasive delivery of MSCs by intravenous infusion is enormous for therapeutic applications, and efficient homing of MSCs to the site of injury is critical for inducing tissue repair and regeneration and would also reduce the clinical dose of cells required to achieve a therapeutic effect. Based on the original anatomic locations of BMMSCs and ATMSCs, they could possibly migrate to different sites after systemic delivery and prove to be more effective for specific applications. The homing ability can be attributed to the chemokine expression of MSCs \[[@CR29]\]. It has been suggested that SDF-1, a small cytokine belonging to the chemokine family, could augment the mobilization, migration, recruitment, and entrapment of MSCs \[[@CR29]\]. Experimental and clinical data have demonstrated that SDF-1 plays an important role in the mobilization and homing of BMMSCs \[[@CR47]\]. In this study, the level of SDF-1 is significantly higher in BMMSCs compared with ATMSCs, showing that BMMSCs have stronger migration capacity. This result implies that less BMMSCs are required to achieve a therapeutic effect. A wide range of expression of chemokines and chemokine receptors of MSCs is needed in further research. The data suggest that BMMSCs and ATMSCs need to be explored further for distinct therapeutic roles. Studying the expression levels of growth factors, cytokines and chemokines could facilitate our understanding of their contribution to cell therapy \[[@CR15]\]. Clearly, more experiments are required to flesh out the ideas described in this paper.

The immunomodulation effect of MSCs is to a large extent mediated via inflammatory cytokines. Several cytokines have been proposed to play a role in the immunomodulation effect of MSCs, including IFN-γ, TNF-α and IL-6 \[[@CR45]\]. It has been demonstrated that IFN-γ is an important cytokine that regulates the immunomodulatory functions of MSCs \[[@CR48]\]. Some studies have reported the influence of media composition or cell source on MSC immunomodulation \[[@CR4],[@CR48]\]. However, few studies to date have examined the effects of cell source based on hPL. Our comparative study shows a stronger expression of IFN-γ in ATMSCs, which suggest that ATMSCs may have superior immunomodulatory effects. Functional study demonstrates that ATMSCs exhibit greater IDO activity compared with BMMSCs, demonstrating that ATMSCs may have more potent immunomodulatory effects than BMMSCs, similar to previous results in FBS medium. Other studies have reported that immunomodulatory-related cytokines such as PGE~2~, TGF-β, and IDO secreted by MSCs, or by immune cells in response to MSCs, play a major role in MSC-mediated immunomodulation \[[@CR35]\]. Clinically, the immunomodulatory properties of MSCs can be used to enhance engraftment and to reduce the incidence of the graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Our data indicates that ATMSCs might be substituted for BMMSCs for treatment of allogeneic conflicts. Further larger and functional studies are needed to confirm the prediction (including other immune-related cytokines and the action on T cells, natural killer cells, and dendritic cells).

Conclusions {#Sec21}
===========

ATMSCs have biological advantages in proliferative capacity, secreted proteins (bFGF, IFN-γ, and IGF-1), and immunomodulatory effects, but BMMSCs have advantages in osteogenic and chondrogenic differentiation potential and secreted proteins (SDF-1 and HGF); these biological advantages should be considered systematically when choosing the MSC source for a specific clinical application.

AT

:   adipose tissue

bFGF

:   basic fibroblast growth factor

BM

:   bone marrow

CFU-F

:   colony-forming unit-fibroblast

CPD

:   cumulative population doubling

DMEM

:   Dulbecco\'s modified Eagle\'s medium

ELISA

:   enzyme-linked immunosorbent assay

FBS

:   fetal bovine serum

HGF

:   hepatocyte growth factor

hPL

:   human platelet lysate

IDO

:   indoleamine 2,3-dioxygenase

IFN

:   interferon

IGF

:   insulin-like growth factor

IL

:   interleukin

IMDM

:   Iscove's modified Dulbecco's medium

MSC

:   mesenchymal stem cell

PBS

:   phosphate-buffered saline

PD

:   population doubling

PGE~2~

:   prostaglandin E~2~

PRP

:   platelet rich plasma

SDF-1

:   stem cell-derived factor-1

TGF

:   transforming growth factor

TNF

:   tumor necrosis factor

VEGF

:   vascular endothelial growth factor
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